139 related articles for article (PubMed ID: 22473690)
1. Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias NA; Kouraklis GP; Giaginis CT; Theocharis SE
Histol Histopathol; 2012 Jun; 27(6):677-92. PubMed ID: 22473690
[TBL] [Abstract][Full Text] [Related]
2. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
4. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
5. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Goel RK; Lukong KE
Cancer Metastasis Rev; 2016 Jun; 35(2):179-99. PubMed ID: 27067725
[TBL] [Abstract][Full Text] [Related]
6. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
7. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
8. The Src signaling pathway: a potential target in melanoma and other malignancies.
Homsi J; Cubitt C; Daud A
Expert Opin Ther Targets; 2007 Jan; 11(1):91-100. PubMed ID: 17150037
[TBL] [Abstract][Full Text] [Related]
9. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
10. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
11. Src kinase inhibitors: promising cancer therapeutics?
Creedon H; Brunton VG
Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
[TBL] [Abstract][Full Text] [Related]
12. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
13. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
[TBL] [Abstract][Full Text] [Related]
14. The many faces of Src: multiple functions of a prototypical tyrosine kinase.
Schwartzberg PL
Oncogene; 1998 Sep; 17(11 Reviews):1463-8. PubMed ID: 9779992
[TBL] [Abstract][Full Text] [Related]
15. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
16. The molecular rationale of Src inhibition in colorectal carcinomas.
Gargalionis AN; Karamouzis MV; Papavassiliou AG
Int J Cancer; 2014 May; 134(9):2019-29. PubMed ID: 23733480
[TBL] [Abstract][Full Text] [Related]
17. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
18. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
Gelman IH
Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
[TBL] [Abstract][Full Text] [Related]
19. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]